Jazz rolls the dice on a billion-dollar gamble on a new drug for SCLC — shooting for a 2020 launch
Two days after filing their cancer drug lurbinectedin in the hunt for an FDA approval, Spain’s PharmaMar has snagged $200 million in cash as a down payment for a new pact with a US partner.
Jazz is handing off the cash and promising $800 million more in a billion-dollar bet that the drug can carve a straight path from positive Phase II data right into the lucrative market for small cell lung cancer — a tough field for drug hunters. Out of the $800 million, $250 million is reserved for regulatory approvals as they steer the drug to a potential 2020 launch.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.